Join the club for FREE to access the whole archive and other member benefits.

Alan Reynolds

Director and Chief Scientific Officer at AKL Therapeutics

Currently Chief Scientific Officer at AKL Therapeutics Ltd (, a company that identifies secondary metabolites of plant origin with proven efficacy and safety, which are then synthesized before undergoing standard pharmaceutical clinical development.

I am an experienced, commercially aware, broad based scientist who can rapidly assimilate knowledge in new therapeutic areas and apply this knowledge to provide strategic input into development of life cycle plans. I have excellent interactive and presentation skills with all functions in a multi-layered pharmaceutical company at all levels of seniority. 

Following a degree in Applied Biology at Brunel University, I worked at Glaxo before undertaking microbiology research at the Royal Free Hospital in London and the University of London School of Pharmacy. I then undertook various roles in Clinical Research at Ayerst/Wyeth, across a range of therapeutic areas including diabetes, CNS, gastroenterology, and inflammation, providing Strategic Scientific Support, Health Technology Assessment, and Clinical Trial design and strategy. I was project lead for all submissions to NICE for the biologic etanercept 

Following promotion to European Clinical Science Director Inflammation in 2006, I was responsible for:

• Strategic scientific input into clinical, commercial and access programmes

• Co-Chair of Optimisation Expert Panel and member of three other Expert Panels

• Project lead for internal training programme

• Membership of various global internal teams (Asset Teams, Publication strategy, investigator initiated protocol approval etc)

Twice I was awarded the President's Achieving Excellence Award

From 2010 I undertook consultancy work for a number of companies involved in thepharmaceutical industry including Pfizer, Napp, UCB, and Norgine. 

I have authored one book chapter, 26 peer reviewed papers, 5 letters to and 45 abstracts

Visit website:


See also: Company AKL Therapeutics - Pharmaceutical Manufacturing company focused on inflammatory diseases

Alan Reynolds News

AKL Therapeutics’ investigational oral senotherapeutics drug APPA beneficial for osteoarthritis

Longevity Technology - 20-Mar-2023

Senescent cells have become one of the most promising targets for healthy aging research